{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adult+Solid+Neoplasm&page=6", "query": { "condition": "Adult Solid Neoplasm", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 1461, "total_pages": 147, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adult+Solid+Neoplasm&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adult+Solid+Neoplasm&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T22:06:59.681Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06586957", "title": "A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Advanced Solid Tumor", "Solid Tumor, Adult", "Metastatic Tumor", "Ovarian Cancer", "Ovarian Neoplasms", "Ovarian Carcinoma", "Metastatic Ovarian Carcinoma", "Endometrial Neoplasms", "Endometrial Diseases", "Metastatic Endometrial Cancer", "Triple Negative Breast Cancer", "Metastatic Endometrial Carcinoma", "Advanced Endometrial Carcinoma", "Advanced Ovarian Carcinoma", "Gastric Cancer", "Advanced Gastric Carcinoma", "Metastatic Gastric Cancer", "Metastatic Gastric Carcinoma", "Small Cell Lung Cancer", "Small Cell Lung Carcinoma", "Triple Negative Breast Neoplasms", "Platinum-resistant Ovarian Cancer", "Platinum-refractory Ovarian Carcinoma", "CCNE1 Amplification", "Hormone Receptor Negative Breast Carcinoma", "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast", "Progesterone-receptor-positive Breast Cancer" ], "interventions": [ { "name": "NKT3964", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NiKang Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 238, "start_date": "2024-09-19", "completion_date": "2029-05", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-21T22:06:59.681Z", "location_count": 19, "location_summary": "Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 16 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Lake Mary", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06586957" }, { "nct_id": "NCT06865664", "title": "FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rhabdomyosarcoma" ], "interventions": [ { "name": "fludarabine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cetuximab", "type": "DRUG" }, { "name": "FGFR4-CAR T Cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "3 Years to 39 Years" }, "enrollment_count": 50, "start_date": "2025-09-22", "completion_date": "2029-04-01", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-21T22:06:59.681Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06865664" }, { "nct_id": "NCT01217411", "title": "RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Solid Neoplasm", "Extensive Stage Lung Small Cell Carcinoma", "HER2/Neu Negative", "HER2/Neu Positive", "Male Breast Carcinoma", "Metastatic Malignant Neoplasm in the Brain", "Recurrent Breast Carcinoma", "Recurrent Lung Non-Small Cell Carcinoma", "Recurrent Lung Small Cell Carcinoma", "Recurrent Melanoma", "Stage IV Breast Cancer AJCC v6 and v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Stage IV Lung Non-Small Cell Cancer AJCC v7" ], "interventions": [ { "name": "Cognitive Assessment", "type": "PROCEDURE" }, { "name": "Gamma-Secretase Inhibitor RO4929097", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Stereotactic Radiosurgery", "type": "RADIATION" }, { "name": "Whole-Brain Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2010-10-01", "completion_date": "2011-11-30", "has_results": true, "last_update_posted_date": "2024-11-19", "last_synced_at": "2026-10-21T22:06:59.681Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01217411" }, { "nct_id": "NCT00585845", "title": "Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Epithelial Mesothelioma", "Adenocarcinoma of the Pancreas", "Carcinoma, Non-Small-Cell Lung", "Adenocarcinoma of the Ovaries" ], "interventions": [ { "name": "CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Anza Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2007-12", "completion_date": "2009-02", "has_results": false, "last_update_posted_date": "2009-02-20", "last_synced_at": "2026-10-21T22:06:59.681Z", "location_count": 3, "location_summary": "Baltimore, Maryland • Bethesda, Maryland • Philadelphia, Pennsylvania", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00585845" }, { "nct_id": "NCT04233567", "title": "Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Cholangiocarcinoma", "Metastatic Malignant Solid Neoplasm", "Refractory Malignant Solid Neoplasm" ], "interventions": [ { "name": "Infigratinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sameek Roychowdhury", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2020-01-16", "completion_date": "2024-12-12", "has_results": true, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-10-21T22:06:59.681Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04233567" }, { "nct_id": "NCT01923337", "title": "Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mucinous Adenocarcinoma of the Colon", "Mucinous Adenocarcinoma of the Rectum", "Recurrent Colon Cancer", "Recurrent Rectal Cancer", "Signet Ring Adenocarcinoma of the Colon", "Signet Ring Adenocarcinoma of the Rectum", "Stage IIIA Colon Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "alisertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2013-08", "completion_date": "2016-10-17", "has_results": false, "last_update_posted_date": "2019-01-04", "last_synced_at": "2026-10-21T22:06:59.681Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01923337" }, { "nct_id": "NCT00016172", "title": "ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "pegylated liposomal doxorubicin hydrochloride", "type": "DRUG" }, { "name": "picoplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-11", "completion_date": "2002-04", "has_results": false, "last_update_posted_date": "2013-06-18", "last_synced_at": "2026-10-21T22:06:59.681Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00016172" }, { "nct_id": "NCT00281853", "title": "Nerve Changes in Patients Who Are Undergoing Chemotherapy or Biological Therapy for Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Neurotoxicity", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "management of therapy complications", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "21 Years to 85 Years" }, "enrollment_count": 15, "start_date": "2005-03", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2010-06-11", "last_synced_at": "2026-10-21T22:06:59.681Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00281853" }, { "nct_id": "NCT00263861", "title": "Nerve Function in Older Diabetic Patients Who Are Undergoing Chemotherapy for Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Neurotoxicity", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "management of therapy complications", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 14, "start_date": "2005-03", "completion_date": "2007-09", "has_results": false, "last_update_posted_date": "2010-06-11", "last_synced_at": "2026-10-21T22:06:59.681Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00263861" }, { "nct_id": "NCT00003451", "title": "Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Precancerous Condition", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "recombinant interleukin-12", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 40, "start_date": "1998-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-01", "last_synced_at": "2026-10-21T22:06:59.681Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003451" } ] }